Rohto Pharmaceutical Co (TSE:4527) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Rohto Pharmaceutical Co Debt-to-Equity?

Rohto Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円4,359 Mil. Rohto Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円5,273 Mil. Rohto Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円240,037 Mil. Rohto Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rohto Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

TSE:4527' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.12
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Rohto Pharmaceutical Co was 0.12. The lowest was 0.02. And the median was 0.05.

TSE:4527's Debt-to-Equity is ranked better than
90.85% of 1640 companies
in the Consumer Packaged Goods industry
Industry Median: 0.41 vs TSE:4527: 0.04

Rohto Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Rohto Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rohto Pharmaceutical Co Debt-to-Equity Chart

Rohto Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.05

0.12

0.06

Rohto Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.06	0.05	0.04	0.04

Competitive Comparison of Rohto Pharmaceutical Co's Debt-to-Equity

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rohto Pharmaceutical Co's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Debt-to-Equity falls into.

Rohto Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rohto Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4177	+	7516)	/	209568
	=	0.06

Rohto Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4359	+	5273)	/	240037
	=	0.04

Rohto Pharmaceutical Co (TSE:4527) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rohto Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rohto Pharmaceutical Co (TSE:4527) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (TSE:4527) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

4527:Mexico

Address

1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666

Website

https://www.rohto.co.jp

Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (TSE:4527) Headlines

No Headlines